About
Compared with tirzepatide injection products , our product SlimEase has three key advantages:
- Less pain: needle-free design achieved 92% patient adherence in a 6-month study;
- Better weight loss effect: 20% mean weight reduction within 36 weeks;
- Easier to use: tablet formulation requires no cold chain storage.
The world's first & only dual-target agonist peptides, clinically proven a 20% weight loss effect in 36 weeks and less side effect compared to last generation product.
Clinical trial results showed an average weight loss of 20.9%
Revolutionary science redefines efficacy. By simultaneously activating both GLP-1 and GIP receptors, it effectively suppresses appetite and enhances metabolic function. This dual-receptor targeting doubles therapeutic efficacy, delivering disruptive weight management solutions.